Reviewer: Deepali Jain, M.D. (see Reviewers page)
Revised: 29 November 2012, last major update August 2012
Copyright: (c) 2001-2012, PathologyOutlines.com, Inc.
● Functionally active and usually malignant endocrine tumour with evidence of D-cell differentiation and clinical symptoms reflecting the diverse pathophysiologic effects of chronic inappropriate secretion of somatostatin (WHO)
● First reported in 1977 (Lancet 1977;1:666, N Engl J Med 1977;296:963, eMedicine)
● Also called delta cell tumors
● Note: somatostatin expression also seen in occur in gangliocytic paraganglioma, poorly differentiated neuroendocrine carcinoma and hereditary neuroendocrine tumors (MEN1)
● Only rarely associated with somatostainoma syndrome (diabetes, cholecystolithiasis, steatorrhea, hypochlorhydria, Endocr Relat Cancer 2008;15:229)
● Hard to localize preoperatively
● May be in duodenal wall
● May have psammoma bodies
3 cm, nonangioinvasive, nonfunctioning somatostatin cell tumor shows moderate nuclear crowding with distinct nucleoli; tumor recurred locally 14 years later with gross invasion and somatostatinoma syndrome
This locally invasive tumor shows a medullary pattern and no significant cellular atypia
Paraganglioma-like growth pattern
Electron microscopy images
D-cell granules in cells of somatostatinoma. Inset: The immunogold reactivity with somatostatin antibodies is seen
End of Pancreas > Neuroendocrine tumors > Somatostatinoma
This information is intended for physicians and related personnel, who understand that medical information is often imperfect, and must be interpreted in the context of a patient's clinical data using reasonable medical judgment. This website should not be used as a substitute for the advice of a licensed physician.
All information on this website is protected by copyright of PathologyOutlines.com, Inc. Information from third parties may also be protected by copyright. Please contact us at copyrightPathOut@gmail.com with any questions (click here for other contact information).